[Use of mycophenolate mofetil (MMF) in kidney transplantation: results of a single center trial].
Mycophenolate Mofetil (MMF) is a new immunosuppressant demonstrated to be effective at the dose of 2 to 3 g/day. The objective of this study was to determine whether MMF could be used at a lower dose with the same efficacy. Two patient groups were studied: 334 patients treated with azathioprine (AZA) and 60 patients treated MMF (at the dose of 750 mg/day, for patients receiving triple combination therapy or 1.5 g/day for those receiving two-agent combination therapy). The rest of the treatment was identical for the 2 groups. The main endpoint was the incidence of acute rejection at 3 months, which was 16% in the MMF group and 35% in the AZA group (p = 0.003). Multivariate analysis confirmed the impact of the type of purine synthesis inhibitor used (AZA or MMF, p = 0.007) on the acute rejection rate at 3 months. This study confirms the value of MMF, even at doses lower than those recommended in the international literature, with improved safety. MMF has now replaced azathioprine in our immunosuppressant protocols.
Pastural
M
M
Service d'Urologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Barrou
B
B
Golmard
J L
JL
Gorichon-Radideau
E
E
Manighetti
J
J
Ourahma
S
S
Benalia
H
H
Mouquet
C
C
Chatelain
C
C
Bitker
M O
MO
D000328:Adult; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use; D003627:Data Interpretation, Statistical; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012086:Reoperation; D013997:Time Factors
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D001379:Azathioprine